Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Published:2017-11-03 Issue:5 Volume:110 Page:479-485
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Tringale Kathryn R¹,Carroll Kate T¹,Zakeri Kaveh²,Sacco Assuntina G³,Barnachea Linda⁴,Murphy James D²

Affiliation:

1. School of Medicine, University of California San Diego, CA

2. Department of Radiation Medicine and Applied Sciences, University of California San Diego

3. Department of Medicine, Division of Hematology and Oncology, Moores Cancer Center, University of California San Diego

4. Department of Pharmacy, University of California San Diego, CA

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/5/479/24797253/djx226.pdf

Reference60 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study;Fitzmaurice;JAMA Oncol,2017

3. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients;Pignon;Radiother Oncol.,2009

4. NCCN guidelines insights: Head and neck cancers, version 2.2017;Adelstein;J Natl Compr Canc Netw.,2017

5. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med.,2016

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck;Japanese Journal of Clinical Oncology;2024-08-29

2. Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives;Frontiers in Pharmacology;2024-06-10

3. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US;JAMA Oncology;2024-03-01

4. Baseline Pan-Immune-Inflammation Value is Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Cancer Treated with Immune Checkpoint Inhibitors;Eurasian Journal of Medicine and Oncology;2024

5. Prospective exploration of a prognostic biomarker of nivolumab for head and neck cancer patients (BIONEXT);2023-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3